Related Experiment Video
Updated: Jul 18, 2026
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Lessons for lupus from tumour necrosis factor blockade.
1Rheumatology Department, Hôpital Robert Ballanger, Aulnay sous Bois, France. m.debandt@ch-aulnay.fr
Lupus
|December 13, 2006
Summary
Tumor necrosis factor (TNF) blockers can impact systemic lupus erythematosus (SLE) by potentially worsening or improving symptoms in patients. This review examines lupus autoantibodies and clinical effects of TNF blockade in SLE and drug-induced SLE.
Area of Science:
- Immunology
- Rheumatology
- Autoimmune Diseases
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by autoantibodies targeting nuclear autoantigens.
- Tumor necrosis factor alpha (TNF-alpha) plays a significant role in SLE pathophysiology.
- Modulation of TNF-alpha via TNF blockers presents a complex therapeutic consideration in SLE patients.
Purpose of the Study:
- To review the impact of TNF blockade on lupus autoantibodies and clinical manifestations in SLE patients.
- To examine instances of drug-induced SLE in non-SLE patients treated with TNF blockers.
- To propose hypotheses for autoantibody induction in rheumatoid arthritis (RA) patients receiving TNF blockers.
Main Methods:
- Literature review focusing on studies involving TNF blockade in SLE and non-SLE patients.
- Analysis of clinical data and autoantibody profiles in patients undergoing TNF-alpha inhibition.
- Exploration of proposed mechanisms for drug-induced autoimmunity.
Main Results:
- TNF blockade can lead to varied clinical outcomes and autoantibody profiles in SLE patients.
- Drug-induced SLE is a recognized phenomenon in non-SLE patients treated with TNF blockers.
- Mechanisms for TNF blocker-induced autoantibody formation in RA patients are hypothesized.
Conclusions:
- The role of TNF-alpha modulation in SLE is multifaceted, requiring careful patient selection and monitoring.
- Understanding the induction of autoimmunity by TNF blockers is crucial for safe therapeutic application.
- Further research is needed to elucidate the precise mechanisms underlying TNF blocker-induced autoimmunity.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.